Brief: AB Science Masitinib Patent Granted In Japan

AB Science SA

18/04/2023 18:27

April 18 (Reuters) - AB Science SA  ABS.PA :
    * ANNOUNCES MASITINIB PATENTGRANTED IN JAPAN FOR TREATMENT
OF
AMYOTROPHIC LATERAL SCLEROSIS
    * TO DATE, THIS PATENT HAS BEEN GRANTED IN 12 REGIONS
INCLUDING
EUROPE, USA, CHINA, ISRAEL AND  MOST RECENTLY JAPAN
    * AS A RESULT, INTELLECTUAL PROPERTY PROTECTION FOR
MASITINIB  IS
SECURED IN ALS UNTIL 2037
    * ORPHAN DRUG DESIGNATION PROVIDES 10 AND 7 YEARS OF MARKET
EXCLUSIVITY IN EUROPE AND US RESPECTIVELY, SUBSEQUENT TO PRODUCT
APPROVAL
    * MASITINIB HAS ALSO RECEIVED ORPHAN DRUG DESIGNATION FOR
ALS FROM
BOTH EUROPEAN MEDICINES AGENCY (EMA) AND US FDA

Source text for Eikon:  ID:nGNE5t4wFm 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))